<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875704</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00112564</org_study_id>
    <secondary_id>OXI-SAD</secondary_id>
    <nct_id>NCT02875704</nct_id>
  </id_info>
  <brief_title>Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy</brief_title>
  <official_title>Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, markers of oxidative stress will be measured in the aqueous humour of&#xD;
      stargardt disease, age related macular degeneration and diabetic retinopathy patients&#xD;
      compared to controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with Stargardt disease, age related macular degeneration (AMD) and diabetic&#xD;
      retinopathy (DR) have decrease in central vision from damage to photoreceptors. One of the&#xD;
      mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific&#xD;
      biomarkers that can be measured in eye fluid (aqueous humor). In this study, these biomarkers&#xD;
      will be assessed in people with Stargardt disease, age related macular degeneration and&#xD;
      diabetic retinopathy, compared to controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline = Day of clinic visit for stargardt disease, AMD, DR patients and day of surgery for patients undergoing cataract surgery. No follow up is required.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Stargardt Disease</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Degeneration (Age Related)</condition>
  <arm_group>
    <arm_group_label>Stargardt disease, AMD, DR patients</arm_group_label>
    <description>Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients without retinal disease who will be undergoing cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anterior Chamber (AC) Tap</intervention_name>
    <description>Aqueous Samples will be collected for measurement of biomarkers</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Stargardt disease, AMD, DR patients</arm_group_label>
    <other_name>AC Tap</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will only be used for measurement of biomarkers of oxidative stress&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stargardt disease, AMD, DR patients and controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent and authorization of use and disclosure of protected health&#xD;
             information&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  For the study group, patients diagnosed with Stargardt disease, age related macular&#xD;
             degeneration and diabetic retinopathy by the investigators, based on clinical&#xD;
             phenotype&#xD;
&#xD;
          -  For the control group, patients with no retinal disease undergoing cataract surgery&#xD;
             will be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulnar Hafiz, MD, MPH</last_name>
    <email>ghafiz1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulnar Hafiz, MD, MPH</last_name>
      <email>ghafiz1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Campochiaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DR</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Stargardt Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

